ReviewDigestive diseases (Basel, Switzerland)2012
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.
Review in Digestive diseases (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Radiomics predicts poorly differentiated hepatocellular carcinoma and uncovers ribosomal-immune dysregulation mechanism.iScience · 2026Article
- Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma.Pharmacogenomics and personalized medicine · 2023Article
- Immunotherapy resistance of lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- [Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Resveratrol exerts antitumor effects by downregulating CD8Oncoimmunology · 2020Article
- Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma.Journal of liver cancer · 2020Review
- Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.Frontiers in oncology · 2020Review
- Review
- Mechanisms of hepatocellular carcinoma progression.World journal of gastroenterology · 2019Review
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.British journal of cancer · 2019Review
- A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.Oncology letters · 2017Article
- Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.Medicine · 2017Observational
- Hepatocellular carcinoma and the risk of occupational exposure.World journal of hepatology · 2016Review
- Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma.Scientific reports · 2015Article
- Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PloS one · 2015Article
- The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.BioMed research international · 2015Review
- Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.BioMed research international · 2014Review
- Role of lymphocytes in liver cancer.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) has been shown to induce several immune suppressor mechanisms in patients. Our laboratory has been investigating different cellular mechanisms of immune suppression in patients with HCC. These suppressor mechanisms range from CD4(+) regulatory T cells, functionally impaired dendritic cells, neutrophils, and monocytes to myeloid-derived suppressor cells. In vitro as well as in vivo studies have demonstrated that abrogation of the suppressor cells enhances or unmasks tumor-specific anti-tumor immune responses. We performed a literature search for immune suppressor cells in HCC, and here we provide a comprehensive summary of the latest studies in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.